脑膜瘤DNA甲基化谱分析揭示具有临床意义的分子亚群
对35例脑膜瘤和5例对照行DNA甲基化谱分析、拷贝数分析、靶向测序及H3K27me3表达检测,无监督层次聚类揭示4个分子亚群(恶性、中间型、良性A、良性B),同一WHO级别内存在分子异质性;甲基化谱对WHO 1级和2级脑膜瘤的无进展生存有显著影响(p=0.0051)。
要点
- DNA甲基化谱分析可识别脑膜瘤4个临床相关分子亚群:恶性、中间型、良性A、良性B。
- 同一WHO级别内存在分子异质性,中间型、良性A和良性B亚群均包含WHO 1级和2级病例。
- 甲基化谱对WHO 1级和2级脑膜瘤的无进展生存有显著影响(p=0.0051)。
核心结论
- 全基因组DNA甲基化谱分析揭示了脑膜瘤具有临床意义的分子亚群及同一级别内的异质性。
- 分子谱分析可能推动脑膜瘤分类、预后预测和治疗策略的范式转变。
研究设计与样本
- 对35例脑膜瘤和5例对照行DNA甲基化谱分析、拷贝数分析、靶向测序及H3K27me3表达检测。
主要发现
- 无监督层次聚类分析揭示4个不同分子亚群:恶性、中间型、良性A和良性B。
- 中间型、良性A和良性B亚群均由WHO 1级和2级病例组成,提示同一级别内存在分子异质性。
- 突变与不同甲基化亚群相关(NF2、AKT1、SMO、TRAF7和pTERT)。
- 22q染色体缺失在所有亚群中均可见,1p/14q共缺失见于50%的恶性和中间型亚群,CDKN2A缺失主要见于恶性亚群(50%)。
- 恶性亚群多数(75%)和其他亚群小部分(中间型25%、良性A 38.5%、良性B 20%)存在H3K27me3缺失,四个亚群间共有38,734个基因表达失调。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Introduction of the classification of brain tumours based on DNA methylation profile has significantly changed the diagnostic approach. Due to the paucity of data on the molecular profiling of meningiomas and their clinical implications, no effective therapies and new treatments have been implemented. METHODS: DNA methylation profiling, copy number analysis, targeted sequencing and H3K27me3 expression was performed on 35 meningiomas and 5 controls. RESULTS: Unsupervised hierarchical clustering (UHC) analysis revealed four distinct molecular subgroups: Malignant; Intermediate; Benign A, and Benign B. Molecular heterogeneity was observed within the same grade as the Intermediate, Benign A, and Benign B subgroups were composed of WHO grade 1 as well as grade 2 cases. There was association of mutations with distinct methylation subgroups (NF2, AKT1, SMO, TRAF7 and pTERT). Loss of chromosome 22q was observed across all subgroups. 1p/14q co-deletion was seen in 50% of malignant and intermediate while CDKN2A loss was predominantly observed in malignant subgroup (50%). Majority of malignant (75%) and a small proportion of other subgroups (Intermediate: 25%, Benign A: 38.5%, and Benign B: 20%) harboured H3K27me3 loss. 38,734 genes were dysregulated amongst the four subgroups. DKFZ classified 71% cases with acceptable score. On survival analysis, methylation profiling had significant impact on progression-free-survival in WHO grade1 and 2 meningiomas (p = 0.0051). CONCLUSION: Genome-wide DNA methylation profiling highlights clinically distinct molecular subgroups and heterogeneity within the same grade of meningiomas. Molecular profiling can usher in a paradigm shift in meningioma classification, prognostic prediction, and treatment strategy.
引用
- Singh J, Sharma R, Shukla N, et al. DNA methylation profiling of meningiomas highlights clinically distinct molecular subgroups. J Neurooncol. 2022. PMID: 36564673. doi:10.1007/s11060-022-04220-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。